The apolipoprotein (APOE) ε4 allele, a well-described genetic risk factor for late-onset Alzheimer disease (AD), is associated with sleep disturbances even in cognitively normal older adults, although it is not clear whether this association is independent of sleep apnea. We sought to extend previous studies by examining whether cognitively normal older adults without self-reported sleep apnea who carry the APOE ε4 allele have altered sleep characteristics compared to noncarriers. Data from N = 36 (APOE ε4 carriers [n = 9], noncarriers [n = 27]) cognitively normal older adults (Clinical Dementia Rating [CDR] scale = 0) without self-reported sleep apnea were used for these analyses. Participants wore an actigraph for 7 days to determine sleep characteristics. The Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS) were used to assess sleep quality and daytime sleepiness, respectively. The APOE ε4 carriers had a higher number of awakenings compared to the noncarriers (P = .02). There was no significant difference in the PSQI global score and the ESS; however, the PSQI subcomponent of daily disturbances was significantly higher in APOE ε4 carriers (P = .03), indicating increased daytime dysfunction is related to disrupted sleep. This study provides evidence that individuals who are cognitively normal and genetically at risk of AD may have disrupted sleep. These findings are consistent with prior studies and suggest that sleep disruption may be present in the presymptomatic stages of AD.
JuYEMcLelandJSToedebuschCD. Sleep quality and preclinical Alzheimer disease. JAMA Neurol. 2013;70(5):587–593.
3.
SterniczukRTheouORusakBRockwoodK. Sleep disturbance is associated with incident dementia and mortality. Curr Alzheimer Res. 2013;10(7):767–775.
4.
HahnEAWangHXAndelRFratiglioniL. A change in sleep pattern may predict Alzheimer disease. Am J Geriatr Psychiatry. 2014;22(11):1262–1271.
5.
LimASKowgierMYuLBuchmanASBennettDA. Sleep fragmentation and the risk of incident Alzheimer’s disease and cognitive decline in older persons. Sleep. 2013;36(7):1027–1032.
EvansDABeckettLAFieldTS. Apolipoprotein E ε4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 1997;277(10):822–824.
8.
StrittmatterMHamannGCramerHReunerCKuntzmannFStrubelD. Neurochemical parameters in senile dementia of the Alzheimer type. A longitudinal study in four cases. Eur Arch Psychiatry Clin Neurosci. 1996;246(2):110–111.
9.
FarrerLACupplesLAHainesJL. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA. 1997;278(16):1349–1356.
10.
AsadaTMotonagaTYamagataZUnoMTakahashiK. Associations between retrospectively recalled napping behavior and later development of Alzheimer’s disease: association with APOE genotypes. Sleep. 2000;23(5):629–634.
11.
CacabelosRRodriguezBCarreraC. APOE-related frequency of cognitive and noncognitive symptoms in dementia. Methods Find Exp Clin Pharmacol. 1996;18(10):693–706.
12.
YesavageJAFriedmanLKraemerH. Sleep/wake disruption in Alzheimer’s disease: APOE status and longitudinal course. J Geriatr Psychiatry Neurol. 2004;17(1):20–24.
13.
BurkeSLMaramaldiPCadetTKukullW. Neuropsychiatric symptoms and Apolipoprotein E: associations with eventual Alzheimer’s disease development. Arch Gerontol Geriatr. 2016;65:231–238.
14.
DrogosLLGillSJTyndallAV. Evidence of association between sleep quality and APOE ε4 in healthy older adults: a pilot study. Neurology. 2016;87(17):1836–1842.
15.
CummingsJL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997;48(5 suppl 6):S10–S16.
ReitanRMWolfsonD. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Vol 4. Reitan Neuropsychology; 1985.
20.
WechslerD.Administration and Scoring Manual for the Wechsler Adult Intelligence Scale—third edition. San Antonio: The Psychological Corporation; 1997.
21.
MorrisJCHeymanAMohsRC. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989;39(9):1159–1165.
22.
GoodglassHKaplanEWeintraubS. Boston Naming Test. Philadelphia, PA: Lea & Febiger; 1983.
23.
SaykinAJShenLYaoX. Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities, and plans. Alzheimers Dement. 2015;11(7):792–814.
24.
BergeGSandoSBRongveAAarslandDWhiteLR. Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry. 2014;85(11):1227–1231.
25.
TsapanouAScarmeasNGuY. Examining the association between Apolipoprotein E (APOE) and self-reported sleep disturbances in non-demented older adults. Neurosci Lett. 2015;606:72–76.
26.
Ancoli-IsraelSColeRAlessiCChambersMMoorcroftWPollakCP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2003;26(3):342–392.
27.
LeePHSuenLK. The convergent validity of Actiwatch 2 and ActiGraph Link accelerometers in measuring total sleeping period, wake after sleep onset, and sleep efficiency in free-living condition. Sleep Breath. 2017;21(1):209–215.
28.
ChoiLLiuZMatthewsCEBuchowskiMS. Validation of accelerometer wear and nonwear time classification algorithm. Med Sci Sports Exerc. 2011;43(2):357–364.
29.
MatthewsCEHagstromerMPoberDMBowlesHR. Best practices for using physical activity monitors in population-based research. Med Sci Sports Exerc. 2012;44(1 suppl 1):S68–S76.
30.
ColeRJKripkeDFGruenWMullaneyDJGillinJC. Automatic sleep/wake identification from wrist activity. Sleep. 1992;15(5):461–469.
31.
Ancoli-IsraelSMartinJLBlackwellT. The SBSM guide to actigraphy monitoring: clinical and research applications. Behav Sleep Med. 2015;13(suppl 1):S4–S38.
32.
BlackwellTAncoli-IsraelSGehrmanPRSchneiderJLPedulaKLStoneKL. Actigraphy scoring reliability in the study of osteoporotic fractures. Sleep. 2005;28(12):1599–1605.
33.
BuysseDJReynoldsCF3rdMonkTHBermanSRKupferDJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213.
34.
JohnsMW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540–545.
35.
ColeJCMotivalaSJBuysseDJOxmanMNLevinMJIrwinMR. Validation of a 3-factor scoring model for the Pittsburgh Sleep Quality Index in older adults. Sleep. 2006;29(1):112–116.
36.
CohenJ. Statistical Power Analysis for the Behavioural Sciences. Hillside, NJ: Lawrence Earlbaum Associates; 1988.
37.
MehraRStoneKLAncoli-IsraelS. Interpreting wrist actigraphic indices of sleep in epidemiologic studies of the elderly: the Study of Osteoporotic Fractures. Sleep. 2008;31(11):1569–1576.
38.
HoneaRAVidoniEHarshaABurnsJM. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis. 2009;18(3):553–564.
39.
WishartHASaykinAJMcAllisterTW. Regional brain atrophy in cognitively intact adults with a single APOE ε4 allele. Neurology. 2006;67(7):1221–1224.
40.
LiuCCKanekiyoTXuHBuG. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118.
41.
KangJELimMMBatemanRJ. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 2009;326(5955):1005–1007.
42.
SpiraAPGamaldoAAAnY. Self-reported sleep and beta-amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013;70(12):1537–1543.
43.
SprecherKEBendlinBBRacineAM. Amyloid burden is associated with self-reported sleep in nondemented late middle-aged adults. Neurobiol Aging. 2015;36(9):2568–2576.
44.
BrangerPArenaza-UrquijoEMTomadessoC. Relationships between sleep quality and brain volume, metabolism, and amyloid deposition in late adulthood. Neurobiol Aging. 2016;41:107–114.
45.
BrownBMRainey-SmithSRBucksRSWeinbornMMartinsRN. Exploring the bi-directional relationship between sleep and beta-amyloid. Curr Opin Psychiatry. 2016;29(6):397–401.
46.
TaiLMThomasRMarottoliFM. The role of APOE in cerebrovascular dysfunction. Acta Neuropathol. 2016;131(5):709–723.
47.
LiuJZhuYSKhanMA. Global brain hypoperfusion and oxygenation in amnestic mild cognitive impairment. Alzheimers Dement. 2014;10(2):162–170.
48.
AloscoMLBrickmanAMSpitznagelMB. Reduced cerebral blood flow and white matter hyperintensities predict poor sleep in heart failure. Behav Brain Funct. 2013;9:42.
LimASYuLKowgierMSchneiderJABuchmanASBennettDA. Modification of the relationship of the apolipoprotein E ε4 allele to the risk of Alzheimer disease and neurofibrillary tangle density by sleep. JAMA Neurol. 2013;70(12):1544–1551.
51.
Alzheimer’s Association. Changing the trajectory of Alzheimer’s disease: a national imperative. 2010.
52.
MarinoMLiYRueschmanMN. Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. Sleep. 2013;36(11):1747–1755.
53.
BuysseDJHallMLStrolloPJ. Relationships between the Pittsburgh Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and clinical/polysomnographic measures in a community sample. J Clin Sleep Med. 2008;4(6):563–571.
